ArticleJournal of global health2025
Association between metabolic syndrome and risk of benign prostatic hyperplasia: a prospective cohort study of 163 975 participants.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.American journal of men's healthPooled it
- Prospective Metabolomic Cohort of 123,037 Men Reveals Lipid Mediators Linking Air Pollution to Benign Prostatic Hyperplasia.Environment & health (Washington, D.C.) · 2026Article
- Reframing Benign Prostatic Hyperplasia as a Cardiometabolic Condition: Should BPH Be Considered a Metabolic Disease?Reviews in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have identified metabolic syndrome (MetS) as a risk factor for benign prostatic hyperplasia (BPH). However, large-scale evidence remains to be established. This study aims to examine the association between MetS and the risk of incident BPH using large-scale cohort data, as well as the underlying biological mechanisms. Methods: We used prospective cohort data from the UK Biobank, including 163 975 male participants. We applied Cox proportional hazards models to estimate the risk of BPH associated with MetS, adjusting for sociodemographic and lifestyle factors. A mediation analysis was conducted to investigate the potential mediating role of various biomarkers. Results: The median follow-up period was 13.40 years, during which 6614 participants (12.03%) with MetS developed BPH. The presence of MetS was associated with an increased risk of BPH (hazard ratio = 1.07; 95% confidence interval = 1.03-1.10). Further analysis showed that longer follow-up duration, individual MetS components (elevated waist circumference, elevated triglycerides, elevated blood pressure, elevated glycated haemoglobin, and reduced high-density lipoprotein cholesterol), and the cumulative number of components were all significantly associated with an increased risk of BPH. Mediation analysis indicated that inflammation, erythrocyte-related biomarkers, liver function, and renal function partially mediated these associations. Conclusions: MetS is a significant risk factor for the incident BPH. Inflammation, erythrocyte-related biomarkers, liver and renal function partially mediate this relationship. Early detection and intervention in MetS may help reduce the risk of developing BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.